NEW YORK, Nov. 06, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is reminding investors that class action lawsuits may be filed on behalf of shareholders of Fulgent Genetics, Inc. (NASDAQ: FLGT), Yatsen Holding Ltd. (NYSE: YSG), Barclays PLC (NYSE: BCS) and Warner Bros. Discovery, Inc. (NASDAQ: WBD). Shareholders have until the deadlines below to petition the court to appear as lead plaintiffs. For more information on each case, see the link provided.

Fulgent Genetics, Inc. (NASDAQ:FLGT)

Class period: March 22, 2019 – August 4, 2022

Lead Plaintiff Deadline: November 21, 2022

Fulgent, along with its subsidiaries, provides COVID-19, molecular diagnostics and genetic testing services to physicians and patients in the United States and internationally. As a result, Fulgent must comply with the federal anti-kickback statute, which prohibits knowingly and intentionally paying “compensations” to induce or reward patient referrals or to transact business in items or services that are payable by the state healthcare programs. and the state Stark statute, which prohibits a physician from making referrals for certain designated health services, including laboratory services, covered by the Medicare program to an entity with which the physician or an immediate family member has a direct or indirect connection financial relationship.

On August 4, 2022, Fulgent reported its second quarter 2022 financial results and announced, among other things, that the US Securities and Exchange Commission (“SEC”) is conducting an investigation into certain of the Company’s reports filed with the SEC from 2018-2018 were made in the first quarter of 2020. The disclosure followed receipt of a civil investigative request from the U.S. Department of Justice “in connection with the investigation of allegations of medically unnecessary laboratory testing, improper billing of laboratory testing…